BioNTech, as my readers will know, was founded as a cancer treatment company. But why did none of its experimental cancer drugs ever make it to a large-scale Phase 3 clinical trial? Why was one of its Phase 2 trials “prematurely ended”? Could it have been that the company’s mRNA-based therapies were in fact accelerating cancers rather than reversing them? Germany’s vaccine and medicines regulator, the PEI, undoubtedly knows. Why shouldn’t we?
For details and discussion, see my new post at The Daily Sceptic here.
Has to be a safety signal, nothing else could explain an abrupt ending.